Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aparlimenol Toripalimab + Fruquintinib + Trifluridine/Tipiracil in Advanced Colorectal Cancer After ≥2nd-Line Failure
ChiCTR2600124276Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab + tuvonralimab, fruquintinib and trifluridine + tipiracil in colorectal adenocarcinoma, sponsored by Ruijin Hospital. Primary endpoints: Progression-free survival, Objective response rate and 2 more. Started May 2026; status: recruiting.
02
Drugs
iparomlimab + tuvonralimabfruquintinibtrifluridine + tipiracil
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600124276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124276.